Gradalis to Participate in 2nd Annual iC3 Life Science Summit
Hosted By BioNorthTX
DALLAS, October 17, 2016 – Gradalis, Inc. today announced that the company will participate in the 2nd Annual iC3 Life Science Summit being hosted by BioNorthTX on October 26, 2016. Mr. Sunil Joshi, President & Chief Executive Officer of Gradalis, will be participating in a panel discussion titled, “Strategies for Success in the Emerging Personalized Medicine Era and a Look into the Future of Cancer Therapeutics and Diagnostics.”
“Gradalis is at the forefront of the development of a highly personlized cellular immunotherapy with our focus on development of Vigil® engineered autologous tumor cell (EATC) technology,” said Mr. Joshi. “I am pleased to participate in this important panel discussion to share our ideas on the best way to develop and commercialize personalized cancer therapeutics.”
Mr Joshi will be available to answer any questions regarding Vigil EATC or Gradalis technology after the panel discussion.
The 2nd Annual iC3 Life Science Summit will be held on October 26, 2016 at the College Park Center, University of Texas at Arlington, 600 S. Center Street, Arlington, TX 76019. For additional information about the summit, please visit www.bionorthtx.org/life-science-summit/.
About Vigil EATC: Vigil is an investigational cellular immunotherapy technology that combines the concepts of genetic engineering with the science of immuno-oncology, to enable an immune response to cancer cells. A patient’s tumor cells are engineered with a plasmid carrying the gene vector for shRNA Furin and GMCSF to elicit a systemic T-cell directed immune response when administered to the patient through intradermal injections. By utilizing the patient’s own tumor as the antigen source, Vigil EATC is designed to elicit an immune response that is specifically targeted and broadly relevant to each patient’s unique tumor antigens. Vigil EATC is being studied in Ewing’s sarcoma and ovarian cancer as a single agent, and in breast cancer, non-small cell lung cancer and melanoma in combination with PD-1/PD-L1 inhibitors. More information about these studies can be found on www.vigilclinicaltrials.com.
About Gradalis: Gradalis is a fully integrated biotechnology company based in Dallas, Texas that focuses on the development, manufacturing, and commercialization of novel proprietary personalized cellular immunotherapies to treat cancer. Gradalis operates a cGMP manufacturing facility in Carrolton, Texas. For more information about Gradalis, Inc. please visit www.gradalisinc.com.
Gradalis® and Vigil® are registered trademarks of Gradalis, Inc.
Chief Financial Officer